ES2058892T3 - Uso de omeprazol como agente antimicrobiano. - Google Patents

Uso de omeprazol como agente antimicrobiano.

Info

Publication number
ES2058892T3
ES2058892T3 ES90902854T ES90902854T ES2058892T3 ES 2058892 T3 ES2058892 T3 ES 2058892T3 ES 90902854 T ES90902854 T ES 90902854T ES 90902854 T ES90902854 T ES 90902854T ES 2058892 T3 ES2058892 T3 ES 2058892T3
Authority
ES
Spain
Prior art keywords
omeprazole
antimicrobial agent
metoxi
benzoimidiazole
campilobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902854T
Other languages
English (en)
Inventor
Masaaki - - - Nishi-Iwat Tomoi
Yoshifumi - Oaza-Nakasoi Ikeda
Yoshiko - Wakazono-Cho Yokota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2058892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hassle AB filed Critical Hassle AB
Application granted granted Critical
Publication of ES2058892T3 publication Critical patent/ES2058892T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE 5-METOXI-2-[[(4-METOXI-3,5-DIMETIL-2-PIRIDINILO) METILO]-1H-BENZOIMIDIAZOL O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE EL EN EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS, ESPECIALES EN AQUELLAS CAUSADAS POR "CAMPILOBACTER PILORI".
ES90902854T 1989-02-09 1990-02-02 Uso de omeprazol como agente antimicrobiano. Expired - Lifetime ES2058892T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1030311A JP2694361B2 (ja) 1989-02-09 1989-02-09 抗菌剤

Publications (1)

Publication Number Publication Date
ES2058892T3 true ES2058892T3 (es) 1994-11-01

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902854T Expired - Lifetime ES2058892T3 (es) 1989-02-09 1990-02-02 Uso de omeprazol como agente antimicrobiano.

Country Status (19)

Country Link
US (1) US5093342A (es)
EP (1) EP0414847B1 (es)
JP (1) JP2694361B2 (es)
KR (1) KR0140236B1 (es)
AT (1) ATE94063T1 (es)
AU (1) AU626641B2 (es)
CA (1) CA2025668C (es)
CY (1) CY1909A (es)
DE (1) DE69003207T2 (es)
DK (1) DK0414847T3 (es)
ES (1) ES2058892T3 (es)
HK (1) HK52196A (es)
HU (1) HU205253B (es)
IE (1) IE65814B1 (es)
IL (1) IL93263A0 (es)
LV (1) LV10577B (es)
MY (1) MY111737A (es)
PH (1) PH26787A (es)
WO (1) WO1990009175A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0382489T3 (da) * 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
ATE209914T1 (de) * 1990-09-14 2001-12-15 Byk Gulden Lomberg Chem Fab Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
AU5019196A (en) * 1995-02-07 1996-08-27 Narayan Krishnarao Athanikar Concomitant treatment with oral bismuth compounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE303809T1 (de) * 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
JP2002509149A (ja) 1998-01-14 2002-03-26 ザ ユーエイビー リサーチ ファウンデイション 細菌ｎａｄシンテターゼ酵素の阻害剤の合成およびスクリーニング方法、その化合物、ならびに細菌ｎａｄシンテターゼ酵素の阻害剤を用いる細菌および微生物感染の治療方法
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc NOVEL FORMULATION, ANTICIPATED COMPLEX IMMEDIATE RELEASE FOR A FAST AND CONTINUOUS SUPPRESSION OF MAGIC ACID
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
PL2003130T3 (pl) 2006-03-10 2012-04-30 Link Genomics Inc Nowa pochodna pirydyny o aktywności przeciwko helicobacter pylori
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
DK2103608T3 (da) 2006-12-18 2012-09-17 Arigen Pharmaceuticals Inc Helicobacter pylori eradikerende middel med inhiberende virkning på mavesyresekretion
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
BRPI1014314A2 (pt) 2009-04-09 2019-09-24 Arigen Pharmaceuticals Inc derivado de tiopiridina, e, composição farmacêutica.
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US8722026B2 (en) 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) * 2014-08-27 2016-06-08 경북대학교 산학협력단 오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
WO1989003829A1 (en) * 1987-10-30 1989-05-05 Aktiebolaget Hässle Omeprazole for treatment of diseases related to bone loss

Also Published As

Publication number Publication date
HU205253B (en) 1992-04-28
CA2025668C (en) 1998-09-15
PH26787A (en) 1992-10-13
IE900418L (en) 1990-08-09
HK52196A (en) 1996-03-29
AU5038190A (en) 1990-09-05
ATE94063T1 (de) 1993-09-15
HU901539D0 (en) 1991-02-28
DE69003207T2 (de) 1994-02-03
JPH02209809A (ja) 1990-08-21
DE69003207D1 (de) 1993-10-14
WO1990009175A1 (en) 1990-08-23
HUT54890A (en) 1991-04-29
EP0414847B1 (en) 1993-09-08
DK0414847T3 (da) 1993-12-13
IL93263A0 (en) 1990-11-29
IE65814B1 (en) 1995-11-15
KR0140236B1 (ko) 1998-06-01
MY111737A (en) 2000-12-30
LV10577B (en) 1995-10-20
LV10577A (lv) 1995-04-20
JP2694361B2 (ja) 1997-12-24
AU626641B2 (en) 1992-08-06
CA2025668A1 (en) 1990-08-10
EP0414847A1 (en) 1991-03-06
US5093342A (en) 1992-03-03
CY1909A (en) 1990-02-02
KR910700048A (ko) 1991-03-13

Similar Documents

Publication Publication Date Title
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
NO932650D0 (no) Forbedringer vedroerende benzotiofener
ES2159591T3 (es) Composicion de liberacion controlada.
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
CA2025668A1 (en) Use of omeprazole as an antimicrobial agent
TW234691B (es)
FI956014L (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
FI910903L (fi) Poroest keramiskt kropp.
ITRM920412A0 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
DE59204364D1 (de) Zahnärztlicher Patientenstuhl.
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
FI922054L (fi) Sjukhusdesinfektionsvagn.
IT1318365B1 (it) Dispositivo di protezione per l'ago per siringa ad uso medicale.
AU3401093A (en) Therapeutic agent for threatened abortion
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
DE69426021D1 (de) Xamonelin-Tartrat
DE68906245D1 (de) Therapeutisches mittel gegen aids.
ES2070148T3 (es) Derivado de la glicerina y utilizacion farmacologica del mismo.
FI965196A7 (fi) HIV-infektion yhdistelmähoito
MX9203221A (es) Compuesto farmacologicamente activo, preparacion y empleo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 414847

Country of ref document: ES